针对HBV的mRNA疫苗:机制,临床前进展和治疗临床进展
Nadezhda A Pechnikova1,2,3, Maria Zafeiriou-Chatziefraimidou4, Malamati Poimenidou4
1Elpida BioPharm P.C., 54636 Thessaloniki, Greece.
Molecular therapy. Nucleic acids
|January 26, 2026
概括
在临床前模型中,信使RNA (mRNA) 疫苗通过清除病毒抗原和DNA来治疗乙型肝炎病毒 (HBV) 感染. 临床试验正在进行中,但免疫过度激活和病毒多样性等挑战需要解决,以获得持久的控制.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 乙型肝炎病毒 (HBV) 感染是肝硬化和肝细胞癌的主要原因.
- 目前对HBV的治疗方法在实现功能性治疗方面受到限制,原因是持续的病毒形式,如ccccDNA和基因组集成.
- 乙型肝炎病毒的持续性也导致宿主免疫反应受损,使治疗结果复杂化.
研究的目的:
- 审查当前的临床前发现和新出现的临床证据,以mRNA为基础的技术,用于HBV治疗和预防.
- 概述未来的战略,以实现持久的病毒控制和有效的预防HBV.
主要方法:
- 在HBV载体小鼠模型中使用脂质纳米粒子 (LNP) mRNA疫苗的临床前研究摘要.
- 对基于mRNA的HBV治疗方法的早期临床试验数据的审查.
- 对HBV治疗的挑战和未来方向的分析.
主要成果:
- 在临床前,针对HBsAg或多价抗原的LNP mRNA疫苗在小鼠模型中显示HBsAg清除和HBV DNA减少.
- 对LNP-mRNA基因编辑 (ARCUS核酶) 和HBx偏差mRNA疫苗的早期临床试验已经开始,有初步的安全数据但没有发表的疗效.
- 确定的挑战包括先天性免疫过度激活,HBV的基因型多样性,以及对组合疗法的需求.
结论:
- 由于其快速发育和免疫刺激性质,mRNA技术为HBV预防和治疗提供了一个多功能平台.
- 尽管有前临床结果和早期临床评估有希望,但有效的HBV治疗仍然面临重大挑战.
- 未来的战略包括新型RNA格式,向传递系统和多模式治疗方案,以持续控制HBV.
相关概念视频
Vaccinations
51.5K
Overview
51.5K
Nonsense-mediated mRNA Decay
11.8K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
11.8K
Regulated mRNA Transport
7.0K
In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing...
7.0K
Nuclear Export of mRNA
8.8K
Before mRNAs are exported to the cytoplasm, it is crucial to check each mRNA for structural and functional integrity. Eukaryotic cells use several different mechanisms, collectively known as mRNA surveillance, to look for irregularities in mRNAs. Irregular or aberrant mRNA are rapidly degraded by various enzymes. If a defective mRNA escapes the surveillance, it would be translated into a protein which would either be non-functional or not function properly. One of the primary irregularities in...
8.8K
pre-mRNA Processing
57.4K
In eukaryotic cells, transcripts made by RNA polymerase are modified and processed before exiting the nucleus. Unprocessed RNA is called precursor mRNA or pre-mRNA to distinguish it from mature mRNA.
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
57.4K
mRNA Stability and Gene Expression
6.6K
The structure and stability of mRNA molecules regulates gene expression, as mRNAs are a key step in the pathway from gene to protein. In eukaryotes, the half-life of mRNA varies from a few minutes up to several days. mRNA stability is essential in growth and development. The absence of the proteins regulating its stability, such as tristetraprolin in mice, can cause systemic issues, including bone marrow overgrowth, inflammation, and autoimmunity.
Cis-acting Elements involved in mRNA stability
Cis-acting Elements involved in mRNA stability
6.6K


